Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial

Vardeny, O. et al. (2022) Dapagliflozin in heart failure with improved ejection fraction: a prespecified analysis of the DELIVER trial. Nature Medicine, 28(12), pp. 2504-2511. (doi: 10.1038/s41591-022-02102-9) (PMID:36522606) (PMCID:PMC9800271)

[img] Text
288465.pdf - Published Version
Available under License Creative Commons Attribution.



With modern treatments for heart failure with reduced ejection fraction (EF), indicative of impaired cardiac systolic function, patients may exhibit an increase in EF. Limited data are available regarding the clinical management of this growing population, categorized as heart failure with improved EF (HFimpEF), which has a high event rate and has been excluded from virtually all prior heart failure outcomes trials. In a prespecified analysis of the DELIVER trial (NCT03619213), of a total of 6,263 participants with symptomatic heart failure and a left ventricular EF >40%, 1,151 (18%) had HFimpEF, defined as patients whose EF improved from ≤40% to >40%. Participants were randomized to 10 mg dapagliflozin or placebo daily and the primary outcome of the trial was a composite of cardiovascular death or worsening heart failure (heart failure hospitalization or an urgent heart failure visit). Participants with HFimpEF had similar event rates to those with an EF consistently >40%. In participants with HFimpEF, dapagliflozin reduced the primary composite outcome (hazard ratio (HR) = 0.74, 95% confidence interval (CI) = 0.56–0.97), first worsening heart failure events (HR = 0.84, 95% CI = 0.61–1.14), cardiovascular death (HR = 0.62, 95% CI = 0.41–0.96) and total worsening heart failure events (rate ratio = 0.68, 95% CI = 0.50–0.94) to a similar extent as for individuals with an EF consistently >40%. These data suggest that patients with HFimpEF who are symptomatic may benefit from the addition of a sodium/glucose cotransporter 2 inhibitor to previously instituted guideline-directed medical therapy to further reduce morbidity and mortality.

Item Type:Articles
Additional Information:AstraZeneca was the sponsor and funder of the DELIVER trial.
Glasgow Author(s) Enlighten ID:Jhund, Professor Pardeep and McMurray, Professor John
Authors: Vardeny, O., Fang, J. C., Desai, A. S., Jhund, P. S., Claggett, B., Vaduganathan, M., de Boer, R. A., Hernandez, A. F., Lam, C. S. P., Inzucchi, S. E., Martinez, F. A., Kosiborod, M. N., DeMets, D., O’Meara, E., Zieroth, S., Comin-Colet, J., Drozdz, J., Chiang, C.-E., Kitakaze, M., Petersson, M., Lindholm, D., Langkilde, A. M., McMurray, J. J.V., and Solomon, S. D.
College/School:College of Medical Veterinary and Life Sciences > School of Cardiovascular & Metabolic Health
Journal Name:Nature Medicine
Publisher:Nature Research
ISSN (Online):1546-170X
Published Online:15 December 2022
Copyright Holders:Copyright © 2022 The Authors
First Published:First published in Nature Medicine 28(12): 2504-2511
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record